Developments in the Treatment of Paroxysmal Nocturnal Hemoglobinuria
Please use the box in the top-right corner of the screen to login or register.
Release Date: August 11, 2022
Expiration Date: August 11, 2023
Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.
The faculty will highlight the latest updates on clinical trials for paroxysmal nocturnal hemoglobinuria (PNH) and provide their practical clinical insights to enhance the implementation of these trials into practice. These experts will discuss new agents, explore how patient management is approached today, and what treatment may look like in the near future.
This program is intended for hematology/oncology physicians, nurse practitioners, pharmacists and clinicians who provide care to patients with paroxysmal nocturnal hemoglobinuria.
Upon completion of this educational activity, participants should be able to:
- Describe the role of complement in the pathophysiology of PNH
- Assess the efficacy of anti-complement treatment in patients with PNH
- Summarize novel agents currently available in clinical practice and those emerging agents in clinical development
- Developments in the Treatment of Paroxysmal Nocturnal Hemoglobinuria – Elizabeth Griffiths, MD, and Ilene C. Weitz, MD
Instructions for Participation and Credit
This activity is eligible for credit through August 11, 2023. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Elizabeth Griffiths, MD
State University of New York
Buffalo, New York
Dr. Elizabeth Griffiths earned her medical degree at the University of North Carolina School of Medicine, Chapel Hill. She completed a five-year medical oncology and hematology fellowship at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital in Baltimore, where she also completed her internal medicine residency. She is an Associate Professor at the State University of New York (SUNY) at Buffalo and a faculty member of the Roswell Park Comprehensive Cancer Center-SUNY Buffalo graduate training programs in the Departments of Pharmacology and Therapeutics, Translational Medicine and Immunology.
Dr. Griffiths is board certified in hematology, oncology, and internal medicine. She is a member of the American Society of Hematology (ASH), the American Association for Cancer Research, the Society for Immunotherapy of Cancer, and the American Society of Oncology. Dr. Griffiths treats patients with blood disorders, specifically acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL), as well as bone marrow failure syndromes, such as aplastic anemia and myelodysplastic syndrome (MDS). Her research is focused on the mechanism of hypomethylating agents (HMAs) in patients with myeloid cancer, specifically the contribution of the immune system to these responses.
Ilene C. Weitz, MD
Professor of Medicine
Keck School of Medicine
University of Southern California
Los Angeles, California
Dr. Ilene Weitz completed her medical degree at the Medical College of Pennsylvania in Philadelphia, followed by an internship and residency in internal medicine at Cedars-Sinai Medical Center. In addition, she conducted a fellowship in hematology/oncology at Scripps Clinic and Research Foundation in La Jolla, California. Dr. Weitz is a Professor of Medicine at the Keck School of Medicine at the University of Southern California (USC). Her practice sites include LAC+USC Medical Center, Keck Hospital of USC, and USC Norris Cancer Hospital.
Dr. Weitz is board certified in internal medicine and hematology. She is a member of the American Medical Women's Association, Los Angeles County Medical Women's Association, American Society of Hematology, and the American Society of Clinical Oncology, among others. Dr Weitz has delivered nationwide lectures and has been published in numerous journals, including the American Journal of Clinical Pathology, Hepatology, Journal of Clinical Oncology, and American Journal of Hematology. Her research and clinical interests include hematologic disorders such as anemias, thrombocytopenia and white blood cell disorders, paroxysmal nocturnal hemoglobinuria (PNH), immune mediated anemias and thrombocytopenia, thrombosis and hemostasis, complement disorder (cold agglutinin disease, PNH, aHUS).
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.50 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-22-010-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
|Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.|
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an accredited continuing education activity to disclose all financial relationships with any ineligible company. The ACCME defines “ineligible companies” as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products by or on patients. A relevant relationship exists if a financial relationship in any amount exists between the person in control of content and an ineligible company; the financial relationship existed during the past 24 months and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. MediCom will identify mitigation strategies for all persons with relevant financial relationships who control content of the educational activity.
Dr. Elizabeth Griffiths has relevant financial relationships related to consulting from AbbVie Inc., Celgene Corporation ‒ A Bristol-Myers Squibb Company, Genentech, Inc., Novartis AG, PicnicHealth, Taiho Pharmaceutical Co., Ltd, and Takeda Oncology, as well as advisory activities from Alexion and PicnicHealth. She has received research grants from Alexion, Apellis, Astex, Celgene Corporation ‒ A Bristol-Myers Squibb Company, Genentech, and Novartis.
Dr. Ilene Weitz has relevant financial relationships related to consulting from Alexion, Apellis, and BioCryst Pharmaceuticals, Inc. She is on the speakers’ bureau for Alexion.
All of the relevant financial relationships listed for these individuals have been mitigated.
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses of products or devices.
Joan Meyer, RN, MHA, Executive Director, Isabelle Vacher, Vice President of Educational Strategy, Lillian McVey, Medical Writer, and Andrea Mathis, Project Manager, planners for this educational activity, have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
Peer reviewer(s) for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at [email protected]
Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from BioCryst US Sales Co., LLC.
©2022 MediCom Worldwide, Inc., 660 Newtown Yardley Rd, Suite 203 · Newtown, PA 18940, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.
Please use the box in the top-right corner of the screen to login or register.